Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Novartis AG (NVS) - free report >>
Roche Holding AG (RHHBY) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novartis AG (NVS) - free report >>
Roche Holding AG (RHHBY) - free report >>
Image: Bigstock
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Roche Holding AG (RHHBY - Free Report) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
The drug is now approved for the treatment of moderate-to-severely persistent asthma in children aged 6 to 11 years, who have had a positive skin test or in vitro reactivity to an airborne allergen, along with symptoms that are inadequately controlled with inhaled corticosteroids.
We note that the drug is already approved for the treatment of allergic asthma patients aged 12 years and older. Xolair is also approved for the treatment of chronic idiopathic urticaria (CIU) in patients aged 12 years and older, who continue to have hives that are not controlled by an H1 antihistamine treatment.
The latest label expansion to include the treatment of a younger group of children should further boost sales of the drug. As per the U.S. Centers for Disease Control and Prevention, asthma affects 6.3 million people under 18, or one in every 12 children in the U.S. Out of this, approximately 60% have allergic asthma. As per estimates from the American Academy of Pediatrics, 70% to 80% of school-aged children with asthma also have allergies. This reflects significant need for treatments in this indication.
ROCHE HLDG LTD Price
ROCHE HLDG LTD Price | ROCHE HLDG LTD Quote
Roche has a collaboration agreement with Novartis AG (NVS - Free Report) for Xolair, under which Novartis is responsible for the commercialization of Xolair outside the U.S., while Roche markets the product in the U.S.
We are impressed by the company's efforts to grow its portfolio beyond oncology and foray into new avenues such as multiple sclerosis and asthma. Roche currently has more than a dozen candidates in its pipeline for diseases like Alzheimer’s disease, spinal muscular atrophy and Parkinson’s disease among others.
The company currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the healthcare sector include Pfizer, Inc. (PFE - Free Report) and Johnson & Johnson (JNJ - Free Report) . Both the stocks carry a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>